Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.
Approval Alert | Enfortumab Vedotin-ejfv Plus Pembrolizumab for Urothelial Cancer
Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
4
Leveraging Novel Software to Further Improve Personalized Cancer Care
5
